ICoLA 2019

ICoLA 2019

The 8th International Congress on Lipid & Atherosclerosis (ICoLA)
The 58th Conference of the Korean Society of Lipid & Atherosclerosis

September 5(Thu.) ~ 7(Sat.), 2019, Conrad Hotel Seoul, Republic of Korea

Extremely low LDL cholesterol, friend or foe?

Prof Kausik K Ray

Imperial Centre for Cardiovascular Disease Prevention,

Department of Primary Care and Public Health,

Imperial College London

London, UK

k.ray@imperial.ac.uk

Abstract

LDL-C is causal and cumulative. Genetic and epidemiological studies show a log linear relationship between cardiovascular risk and absolute differences in LDL-C. Trials of lipid lowering therapies show a similar log linear relationship between risk and LDL-C difference.

In nature among those with PCSK9 gene mutations or abetalipoproteinaemia risk of CAD is extremely low. Trials of statins, eztemibe, and PCSK9 have not shown any relationship between reductions in LDL-C and adverse cardiovascular outcomes in particular stroke risk is lower. In observational studies from trials lower appperes to be safe and beneficial from a cardiovascular standpoint when all is safe.

Keywords

LDL-C, genetics, statins, ezetimibe, PCSK9, safety, efficacy

Secretariat People & Value, Inc., #1001 161-17 Magokjungang-ro, Gangseo-gu, Seoul 07788, Republic of Korea Tel: +82-2-2135-3617 Fax: +82-2-564-2123 E-mail: secretariat@icola.org